ESC 2026: Tirzepatide 5mg sustains cardiometabolic benefit with weight maintenance
On 28 August, at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, a post-hoc analysis of the …
Post
-
-
Why CMC readiness is becoming central to biopharma licensing deals
Biopharma licensing is becoming more operational. Buyers and partners still begin with the quality of the science, but they also …
-
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
US President Donald Trump has struck a new set of Most Favored Nation (MFN) drug pricing deals with several mid-size …
-
Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal
Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease …
-
PharmaEssentia’s Besremi receives FDA approval for ET
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET). This …
-
PharmaEssentia’s Besremi receives FDA approval for ET
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET). This …
-
Kazia closes oversubscribed offering to fund paxalisib’s clinical development
Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds …
-
ESC 2026: Evidence supporting SGLT2 inhibitors and finerenone in heart failure grows
At the 2026 European Society of Cardiology (ESC) Scientific Sessions, hosted in Munich, Germany, researchers and care providers assembled to …
-
ESC 2026: Aficamten breaks new ground in nonobstructive HCM
This year at the European Society of Cardiology (ESC) Scientific Sessions, findings from the ACACIA-HCM trial explored the effect of …
-
ESC 2026: Evolocumab explores new frontiers in CV disease prevention
This year at the European Society of Cardiology (ESC) Scientific Sessions, new findings were presented from a pre-specified analysis of …
-
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total …
-
ESC 2026: Statins show worth despite emergence of PCSK9 inhibitors
A type of statin significantly reduces the risk of major cardiovascular events in elderly patients, demonstrating their continued importance despite …
-
Myasthenia gravis market to reach $13.0bn across 7MM by 2034
The myasthenia gravis (MG) market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is …
-
Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
The US Food and Drug Administration (FDA) has approved Eli Lilly’s blockbuster type 2 diabetes therapy, Mounjaro (tirzepatide), as a …
-
FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
Priovant Therapeutics has secured approval from the US Food and Drug Administration (FDA) for its oral therapy Lisraya (brepocitinib) in …
